{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:32:17Z","timestamp":1791685937480,"version":"4.3.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.xphs.2026.104487","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T15:13:01Z","timestamp":1788016381000},"page":"104487","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Biowaiver monograph for immediate-release solid oral dosage forms: Dabigatran etexilate"],"prefix":"10.1016","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9359-7534","authenticated-orcid":false,"given":"Takuto","family":"Niino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamaki","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertil","family":"Abrahamsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2519-1179","authenticated-orcid":false,"given":"Naseem A.","family":"Charoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Cristofoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Langguth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6875-3899","authenticated-orcid":false,"given":"Alan","family":"Parr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5274-4314","authenticated-orcid":false,"given":"James E.","family":"Polli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod P.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Dressman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2957-6287","authenticated-orcid":false,"given":"Atsushi","family":"Kambayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2026.104487_bib0001","doi-asserted-by":"crossref","unstructured":"World Health Organization. The selection and use of essential medicines,2025. World Health Organization; 2025. doi:10.2471\/B09474","DOI":"10.2471\/B09474"},{"issue":"12","key":"10.1016\/j.xphs.2026.104487_bib0003","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xphs.2026.104487_bib0005","unstructured":"Pharmaceuticals and Medical Devices Agency. Guideline for bioequivalence studies for different strengths of oral solid dosage forms index. 2020."},{"key":"10.1016\/j.xphs.2026.104487_bib0006","unstructured":"Pharmaceuticals and Medical Devices Agency. Guideline for bioequivalence studies for formulation changes of oral solid dosage forms index. 2020."},{"key":"10.1016\/j.xphs.2026.104487_bib0007","unstructured":"ICH. Biopharmaceutics classification system-based biowaivers M9 final version. 2019."},{"key":"10.1016\/j.xphs.2026.104487_bib0008","unstructured":"The United States Pharmacopeial Convention. Proposed interim revision announcements. NPharmacopeial Forum. Published online 2010."},{"key":"10.1016\/j.xphs.2026.104487_bib0010","unstructured":"US Food and Drug Administration. Highlights of prescribing information. Published online June 17, 2025. Accessed May 3, 2026. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=022512"},{"issue":"2","key":"10.1016\/j.xphs.2026.104487_bib0011","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1177\/2168479018769301","article-title":"How does \u201cregulatory practice\u201d create discrepancies in drug label information between Asian and Western countries? Different label information for direct oral anticoagulants approved in the United States, Europe, Korea, and Japan","volume":"53","author":"Cho","year":"2019","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.xphs.2026.104487_bib0012","unstructured":"US Food and Drug Administration. Center for drug evaluation and research application number: 214358Orig1s000 clinical review(S). 2020."},{"key":"10.1016\/j.xphs.2026.104487_bib0013","unstructured":"European Medicines Agency. CHMP assessment report for Pradaxa. 2008. Accessed January 24, 2026. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/pradaxa-epar-public-assessment-report_en.pdf"},{"key":"10.1016\/j.xphs.2026.104487_bib0014","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jpba.2015.03.009","article-title":"Development of liquid chromatographic method for the analysis of dabigatran etexilate mesilate and its ten impurities supported by quality-by-design methodology","volume":"111","author":"Pantovi\u0107","year":"2015","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.xphs.2026.104487_bib0015","unstructured":"US Food and Drug Administration. Center for drug evaluation and research application number: 22-512 chemistry review(S). 2010."},{"key":"10.1016\/j.xphs.2026.104487_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106447","article-title":"The polymorph landscape of dabigatran etexilate mesylate: taking the challenge to bring a metastable polymorph to market","volume":"186","author":"Sieger","year":"2023","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2026.104487_bib0017","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/dmd.107.019083","article-title":"The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans","volume":"36","author":"Blech","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.xphs.2026.104487_bib0018","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1124\/dmd.113.053561","article-title":"Impact of endogenous esterase activity on In Vitro P-glycoprotein profiling of dabigatran etexilate in caco-2 monolayers","volume":"42","author":"Ishiguro","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.xphs.2026.104487_bib0019","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/0006-291X(91)91647-U","article-title":"Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells","volume":"175","author":"Artursson","year":"1991","journal-title":"Biochem Biophys Res Commun"},{"issue":"06","key":"10.1016\/j.xphs.2026.104487_bib0020","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1160\/TH09-11-0758","article-title":"Dabigatran etexilate \u2013 a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity","volume":"103","author":"van","year":"2010","journal-title":"Thromb Haemost"},{"issue":"1_suppl","key":"10.1016\/j.xphs.2026.104487_bib0021","doi-asserted-by":"crossref","DOI":"10.1177\/1076029609343004","article-title":"Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor","volume":"15","author":"Stangier","year":"2009","journal-title":"Clin Appl Thromb\/Hemost"},{"key":"10.1016\/j.xphs.2026.104487_bib0023","unstructured":"Nhi Beasley. Center for drug evaluation and research application number: 22-512 MEDICAL REVIEW(S) addendum to clinical review for NDA 22-512. 2010."},{"issue":"2","key":"10.1016\/j.xphs.2026.104487_bib0024","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1124\/dmd.113.054353","article-title":"Identification of carboxylesterase-dependent dabigatran etexilate hydrolysis","volume":"42","author":"Laizure","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.xphs.2026.104487_bib0025","unstructured":"Etexilate D, Farma L. Committee for Medicinal Products for Human Use (CHMP) Assessment Report. www.ema.europa.eu\/contact"},{"key":"10.1016\/j.xphs.2026.104487_bib0026","unstructured":"Accord Healthcare S.L.U. World trade center moll de Barcelona S\/N Edifici Est. Committee for Medicinal Products for Human Use (CHMP) Assessment Report. www.ema.europa.eu\/contactTelephone+31"},{"issue":"5","key":"10.1016\/j.xphs.2026.104487_bib0027","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1177\/0091270005274550","article-title":"Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement","volume":"45","author":"Stangier","year":"2005","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.xphs.2026.104487_bib0028","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00003088-200847010-00005","article-title":"Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects","volume":"47","author":"Stangier","year":"2008","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"10.1016\/j.xphs.2026.104487_bib0029","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1111\/j.1538-7836.2011.04498.x","article-title":"Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial","volume":"9","author":"Liesenfeld","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1016\/j.xphs.2026.104487_bib0031","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00003088-200847050-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate","volume":"47","author":"Stangier","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.xphs.2026.104487_bib0032","unstructured":"Sabine Landerer TF. Pharmaceutical oral dosage forms comprising dabigatran etexilate and its pharmaceutically acceptable salts. Published online April 19, 2017. Accessed March 2, 2026. https:\/\/patents.google.com\/patent\/EP2588090B1\/en"},{"issue":"4","key":"10.1016\/j.xphs.2026.104487_bib0033","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2013.07.104","article-title":"The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients","volume":"63","author":"Reilly","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.xphs.2026.104487_bib0034","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1538-7836.2004.01100.x","article-title":"A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial","volume":"3","author":"ERIKSSON","year":"2005","journal-title":"J Thromb Haemost"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926003370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926003370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:52:56Z","timestamp":1791345176000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354926003370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0022354926003370"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104487","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biowaiver monograph for immediate-release solid oral dosage forms: Dabigatran etexilate","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104487","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104487"}}